Press Releases - IGC Pharma, INC.

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

110_Ascendiant-Capital-Markets-Raises-IGC-Pharma-Price-Target-to-$6.00,-Citing-CALMA-Progress-and-Q4-2026-Topline-Catalyst

Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst

August 28, 2026

109_IGC-Pharma-Reports-Q2-2026-Results-as-CALMA-Alzheimer’s-Trial-Moves-Within-Six-Randomizations-of-Enrollment-Closure

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure

August 17, 2026

108_IGC-Pharma-Strengthens-Regulatory-Readiness-as-Phase-2-CALMA-Alzheimer’s-Trial-Approaches-Enrollment-Closure-and-Q4-Topline-Readout

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout

August 11, 2026

107_IGC-Pharma-Expands-Regulatory-Readiness-as-Phase-2-Alzheimer’s-Trial-Advances-Toward-Topline-Results

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

106_IGC-Pharma-to-Present-Seven-AI-Driven-Research-Studies-at-the-Alzheimer

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow

105_IGC-Pharma-CEO-and-Principal-Financial-Officer-Purchase-More-Than-$1.15-Million-of-Common-Stock-Directly-from-the-Company

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

IGC-Pharma-Reaches-90-Enrollment-in-Phase-2-CALMA-Trial-Evaluating-IGCAD1-for-Agitation-in-Alzheimers-Dementia

IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow

103_IGC-Pharma-Reaches-90-Enrollment-in-Phase-2-CALMA-Trial-Evaluating-IGCAD1-for-Agitation-in-Alzheimers-Dementia

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

102_Ascendiant-Capital-Markets-Raises-IGC-Pharma-Price-Target-to-$5.50,-Citing-Clinical-Progress-and-2026-Catalysts

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

101_IGC-Pharma-Expands-Phase-2-CALMA-Trial-with-New-Clinical-Site-at-Icahn-School-of-Medicine-at-Mount-Sinai

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

100_IGC-Pharma-Reports-First-Quarter-2026-Financial-Results-with-CALMA-Phase-2-in-the-final-stage,-with-80Enrollment

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

99_IGC-Pharma-Reaches-85-Enrollment-in-Phase-2-CALMA-Trial-Evaluating-IGC-AD1-for-Alzheimer’s-Agitation

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

98_IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

97_IGC-Pharma-Adds-Kerwin-Medical-Center-in-Dallas-to-Phase-2-CALMA-Trial-as-Enrollment-Advances-Toward-Completion

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

96_IGC-Pharma-Secures-Psilocybin-Research-Authorization,-Expanding-Focus-on-Neuropsychiatric-Symptoms-in-Dementia-

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

95_IGC-Pharma-Reports-Approximately-80-Patient-Enrollment-in-Phase-2-CALMA-Alzheimers-Agitation-Trial-

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout